Open Access Full Text Article

RETRACTION

## The Long Non-Coding RNA SBF2-ASI Exerts Oncogenic Functions in Gastric Cancer by Targeting the miR-302b-3p/E2F Transcription Factor 3 Axis [Retraction]

Liang C, Yue C, Liang C, et al. The long non-coding RNA SBF2-AS1 exerts oncogenic functions in gastric cancer by targeting the miR-302b-3p/E2F transcription factor 3 axis. *Onco Targets Ther.* 2019:12:8879–8893.

At the request of the authors, the Editor-in Chief and Publisher of *OncoTargets and Therapy* wish to retract this published article.

On review of their published article the authors observed instances of image duplication in some of the figures. A summary of their concerns follows:

Figure 4A, overlap of MKN28 (0h, shNC) and MKN28 (0h, sh2).

Figure 4A, overlap of MKN28 (24h, sh2) and HGC27 (24h, sh2).

Figure 7B, the upper half of (0h, E2F3 + miR-302b-3p) appears identical to the lower halves of (0h, miR-302b-3p) and (0h, E2F3).

The authors were unable to provide a satisfactory response regarding the issues relating to the image duplication and the editor determined the findings of the study were no longer valid and advised the article needed to be retracted. The authors have agreed with this decision and wish to apologize for this error.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

## **OncoTargets and Therapy**

## **Dove**press

2523

**Publish your work in this journal** 

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal



OncoTargets and Therapy 2020:13 2523

© 2020 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for Commercial use of this work, peaks ese paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).